SCHEMBL6720489

SCHEMBL6720489

Cc1noc(C)c1S(=O)(=O)Nc1cccc(C2=NCCc3cc(Cl)ccc32)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
BRD4 O60885 2/20 0.46
BRD2 P25440 2/20 0.46
BRD3 Q15059 2/20 0.46
NR3C2 P08235 1/20 0.45
LMNA P02545 5/20 0.45
HTT P42858 3/20 0.45
PKM P14618 2/20 0.45
POLB P06746 1/20 0.45
MAPK10 P53779 4/20 0.44
MAPK9 P45984 1/20 0.44
MAPK14 Q16539 1/20 0.44
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718857 0.93 ALDH1A1 (0.48) ALDH1A1BRD4BRD2BRD3NR3C2
SCHEMBL6720382 0.89 ALDH1A1 (0.48) ALDH1A1BRD4BRD2BRD3NR3C2
SCHEMBL6718862 0.89 ALDH1A1 (0.52) ALDH1A1BRD4BRD2BRD3NR3C2
SCHEMBL6720559 0.84 ALDH1A1 (0.48) ALDH1A1BRD4BRD2BRD3NR3C2
SCHEMBL7213745 0.83 BRD4 (0.49) ALDH1A1BRD4BRD2BRD3LMNA
SCHEMBL6724570 0.82 LMNA (0.46) ALDH1A1LMNAHTTPKMPOLB
SCHEMBL6724930 0.81 GSPT1 (0.45) BRD4BRD2BRD3MAPK10MAPK9
SCHEMBL6718350 0.79 MAPK10 (0.40) MAPK10MAPK9MAPK14GAA
SCHEMBL6720414 0.79 ALDH1A1 (0.47) ALDH1A1LMNAHTTPKMPOLB
SCHEMBL6718000 0.78 CYP19A1 (0.46) ALDH1A1LMNAPKMMAPK10MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A ALDH1A1 213/4885BRD4 1595/4885BRD2 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.